• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Debate Rages On Over ‘Black Box’ Warning on Antidepressants

Debate Rages On Over ‘Black Box’ Warning on Antidepressants

November 1, 2014
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Short Description:

Debate Rages On Over ‘Black Box’ Warning on Antidepressants

Background:

It’s been 10 years since the US Food and Drug Administration (FDA) put a so-called ‘black box’ warning on certain antidepressants because of fears they can cause suicidal thoughts and behavior.

The psychiatric community continues to debate the value of that warning, and a pair of opposing viewpoints was recently featured in the New England Journal of Medicine. One called for removal of the warnings (http://bit.ly/1EC0cJb), while the other, written by a medical reviewer at the FDA and proponent of broader antidepressant labeling, challenged the safety claims of the anti-black box crowd (http://bit.ly/1olxGr1).

All antidepressants carry a warning label cautioning users that the medications may increase the risk of suicidal thoughts and behaviors in children and young adults. The FDA required the black box warnings in 2004 after data emerged linking the drug paroxetine (Paxil) to suicidal thoughts. Opponents argue the warnings overstate the real risk and discourage physicians from prescribing them to patients who could really benefit from antidepressants.

A recent report in Time magazine (http://ti.me/1oHlaCw) interviewed 17 leaders in the psychiatry field and asked their opinions: 11 said the FDA should remove the warnings; two said the media has overblown the risk, resulting in more panic than is necessary; and four support the warning labels. Among those four, three were involved in the FDA’s original decision to issue the black box warnings.

Despite the controversy, the FDA has no plans to reconsider the warnings, according to the Time article.

Related content:
Black Box Warning in Children and Adolescents

Child Psychiatry
KEYWORDS antidepressants news_of_note risk_management
    www.thecarlatreport.com
    Issue Date: November 1, 2014
    SUBSCRIBE NOW
    Table Of Contents
    FDA Notice: Be Wary of Some Generic Versions of Concerta
    Omega Fatty Acids Might Help Kids with Attention Deficits
    Pediatrician Policy Statement: Schools Should Start Later for Healthier Teens
    CDC Study: Kids Are Flocking to e-Cigarettes
    Following Release from Prison, Suicide Risk Eighteen Times Higher
    Debate Rages On Over ‘Black Box’ Warning on Antidepressants
    Vyvanse: A Look at America’s Most Prescribed Stimulant
    Intuniv: Exorbitant, Sedating, and Second-Line
    A Balanced Approach to Treating ADHD
    Pet Therapy for College Students
    Danish Study Explains Most of Autism’s Rise
    To Prevent Depression in Teens, Teach About Change
    Daily Marijuana Use by Teens Creates Life Problems
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.